Can An Antibody Cocktail Block COVID-19 Infection? Regeneron’s Warp Speed Research Aims To Find Out Soon
Could Be Available In Late Summer
Executive Summary
The only non-vaccine project backed by Operation Warp Speed, Regeneron’s antibody cocktail could play a crucial role in the fight against SARS-CoV2 – if it works. Clinical development chief David Weinreich talks to Scrip about its innovative adaptive trial collaboration, and how it could provide answers in a matter of months.
You may also be interested in...
Finance Watch: CureVac’s IPO Is Ready For Launch
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Regeneron Pipeline Progresses On Several Fronts Despite COVID-19 Focus
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.